🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
This is a first-in-human study to investigate the safety, tolerability, pha...
Status
Completed
Location
Novartis Investigative Site
Start Date
2013-01-07
Trial ID
NCT02089087
This study was to compare CFZ533 to tacrolimus (TAC) in prevention of organ...
Status
Completed
Location
Novartis Investigative Site
Start Date
2018-11-28
Trial ID
NCT03663335
This study did evaluate the safety,tolerability and preliminary therapeutic...
Status
Completed
Location
Novartis Investigative Site
Start Date
2014-10-22
Trial ID
NCT02291029
This study was to evaluate the safety, tolerability, pharmacokinetics, phar...
Status
Completed
Location
Novartis Investigative Site
Start Date
2018-09-12
Trial ID
NCT03610516
The study was a Phase 2, multicounty, multicenter, non-confirmatory, invest...
Status
Completed
Location
Novartis Investigative Site
Start Date
2019-11-08
Trial ID
NCT04129528
This study is designed to evaluate the safety, tolerability, pharmacokineti...
Status
Completed
Location
Novartis Investigative Site
Start Date
2018-12-19
Trial ID
NCT03656562
Treatments Being Tested
This study was to evaluate the safety, efficacy, pharmacokinetics (PK) and ...
Status
Completed
Location
North GA Rheumatology Group PC
Start Date
2019-10-01
Trial ID
NCT03905525
This study will evaluate the safety and tolerability of iscalimab at two do...
Status
Completed
Location
North GA Rheumatology Group PC
Start Date
2021-01-05
Trial ID
NCT04541589
The main purpose of this study is to assess preliminary efficacy and safety...
Status
Active Not Recruiting
Location
Olympian Clinical Research
Start Date
2019-02-27
Trial ID
NCT03827798
The purpose of this study is to evaluate safety, tolerability, pharmacokine...
Status
Completed
Location
Novartis Investigative Site
Start Date
2015-09-29
Trial ID
NCT02565576